Spring direct naar de hoofdnavigatie of de inhoud

Raygene Martier

Patent attorney

‘Optimally capitalize on your innovation. Activate your ideas.’
Raygene Martier

Raygene Martier

  • Life Sciences
  • Trainee Patent Attorney

Raygene Martier studied  Biomolecular Sciences  at VU Amsterdam with majors in molecular biology and  biochemistry. He gained work experience in both academia and industry.

Continue reading

He  has extended his  knowledge in areas such as gene therapy, neurology,  virology, microbiology, immunology, biochemistry, molecular biology, cell biology, diagnostics and medical biotechnology. He started his PhD in 2015 at the gene therapy company uniQure,  where he was responsible for development of RNAi-based gene therapies for differed neurodegenerative disorders. Here he also had the opportunity to support the IP department and became aware that R&D and IP go hand in hand.

Raygene  joined V.O. in 2019 as trainee patent attorney . He enjoys  being at the interface between science and Patent Law.

Education

  • PhD in RNAi-based gene therapies for  neurodegenerative disorders, Leiden U niversity/uniQure (2020)
  • MSc in Biomolecular Sciences, VU Amsterdam (2013)
  • BSc in Biotechnologie, Noordelijke Hogeschool Leeuwarden (2009)

Publications

  • Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, Konstantinova P. (2019). Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic. Acids.14: 593-608.
  • Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, Konstantinova P. (2019). Targeting RNA-Mediated toxicity in C9orf72 ALS and/or FTD by RNAi-Based gene Therapy. Mol. Ther. Nucleic. Acids.16: 26-37
  • Martier R, Sogorb Gonzalez M, Stricker-Shaver J, Hübener-Schmid J, Keskin S, Witjas J, van Deventer SJ, Konstantinova P, Phuc Nguyen H, Evers MM. (2019). Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease. Mol. Ther. Methods & Clinical Development Acids. https://doi.org/10.1016/j.omtm.2019.10.008.
  • Pietersz KL, Martier R, Baatje SM, Liefhebber JM, Brouwers CC, Pouw SM, Fokkert L, Lubelski J, Petry H, Martens GJM, van Deventer SJ, Konstantinova P, Blits B. (2019). Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery. Gene Ther. Under submission.
  • Liefhebber, J., Martier, R., Van der Zon, T., Keskin, S., Huseinovic, A., Lubelski, J., Blits, B., Petry, H., Konstantinova, P. (2019) In depth characterization of a Mifepristone regulated expression system for AAV5-mediated gene therapy in the liver. Mol. Ther. Methods & Clinical Development.13: 512-525.
  • Keskin S, Brouwers CC, Sogorb-Gonzalez M, Martier R, Depla JA, Vallès A, van Deventer SJ, Konstantinova P, Evers MM. (2019) AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patientderived neuronal cultures and astrocytes. Mol. Ther: Methods & Clinical Development. doi: https://doi.org/10.1016/j.omtm.2019.09.010.
  • Miniarikova J, Zimmer V, Martier R, Brouwers C. C, Pythoud C, Richetin K, Konstantinova P. (2017). AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Ther. 24: 630-639.
  • Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Konstantinova P. (2016). Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington’s Disease. Mol. Ther. Nucleic Acids: e297.
  • MacZuga P, Verheij J, Van Der Loos C, Van Logtenstein R, Hooijer G, Martier R, Konstantinova P. (2014). Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. Gene. Ther. 21: 60-70.
  • Staszewski O, Baker RE, Ucher AJ, Martier R, Stavnezer J, Guikema JEJ. (2011). Activation-Induced Cytidine Deaminase Induces Reproducible DNA Breaks at Many Non-Ig Loci in Activated B Cells. Molecular Cell. 41(2): 232-242.

Languages

  • Dutch
  • English
  • Spanish
  • Papiamento

Also see these experts

Hajo Kraak

Hajo Kraak

  • European Patent Attorney
  • Dutch Patent Attorney
  • Partner
Jetze Beeksma

Jetze Beeksma

  • European Patent Attorney
  • Dutch Patent Attorney
  • Associate
More experts

News

New on Kluwer Patent Blog: Bayer Intellectual Property GmbH vs. Ceva Santé Animale SA, Nederland

Bayer was not granted an injunction in preliminary proceedings because the Court found that there was a serious chance that Bayer’s patent would be held invalid.Continue reading

New on Kluwer Patent Blog: Recordati Ireland Limited, EPO

A claim defining a compound as having a certain purity would lack novelty over a prior art disclosure describing the same compound only if the prior art disclosed the claimed purity at least implicitly.Continue reading

New on Kluwer Patent Blog: R-Pharm International, LLC, EPO

A request for re-establishment should be filed within two months of the date of removal of non-compliance.Continue reading

Events

Innovation for Health 2020

World Trade Center (WTC) Rotterdam, Beursplein, Rotterdam

Innovation for Health is the premier event for key players in Health & Life Sciences in the Netherlands and Belgium. It provides a unique opportunity to meet leading innovators, to catch up on the latest trends, to present cutting-edge innovations and to engage leaders and decision makers in Life Sciences & Health. Continue reading

2nd LIFE-ON-CHIP Conference 2020

Provincie Vlaams-Brabant - Provinciehuis Leuven, Provincieplein, Leuven, Belgium

Micro- and nanotechnology, artificial intelligence, design thinking, robotics, novel manufacturing technologies and big data have made major impacts across all industries, but perhaps their greatest potential impact will be in health and life sciences. Continue reading

MIP International Patent Forum 2020

etc.venues St Paul's, London, UK

As MIP’s flagship event, over 300 IP counsel register every year, connecting senior patent counsel with their peers from across Europe, Asia and the Americas. Join this event to expand your international business network. Continue reading